Don't miss out on these discounted products!
Act fast before the sale ends!
The following products are currently out of stock
Don't miss out on these discounted products!
Act fast before the sale ends!
The following products are currently out of stock
This section outlines the evolution and milestones of Behemothlabz from its founding in 2014 to its continued growth and innovation in 2024.
This section provides all our contact details, encouraging you to reach out for assistance or inquiries. It encompasses live chat, phone support, and email options, ensuring accessibility for all.
Discover all you need to know to partner with us and promote our products to earn rewards.
In our FAQs section, we have compiled answers to the questions we frequently receive. Quickly find information about our company, products, and policies. If you have any questions, you might find the answer here before reaching out to us directly.
In our Quality Control and Testing section, we uphold Behemothlabz’s Commitment to Quality by meticulously detailing our procedures.
Sign up Here for our regular newsletter and stay updated.
$163.48 – $174.98
Earn 163 - 175 points upon purchasing this product.
BehemothLabz proudly presents Atlantis Capsules, a blend of advanced research compounds meticulously crafted for scientific exploration. Each capsule contains precise quantities of ITPP (50mg), GW0742 (25mg), and SR9011 (30mg), formulated to potentially enhance oxygen delivery, support muscle recovery, and promote metabolic health. Available in two variants: 105mg/20ct/2.1g and 105mg/40ct/4.2g, Atlantis Capsules offer researchers a reliable tool to investigate these compounds’ potential applications.
Atlantis Capsules consist of a blend of top-notch research compounds, with every capsule containing specific ingredients:
It is also available in the following variants: 105mg/20ct/2.1g and 105mg/ 40ct/ 4.2g
ITPP (inositol tris pyrophosphate) is a synthetic compound that strengthens oxygen delivery to tissues by functioning as an allosteric effector of hemoglobin. It has been studied for its anti-cancer properties as well as its ability to improve endurance and physical performance. (R) (R)
The effects of ITPP on exercise performance in mice were investigated in a 2015 study published in the British Journal of Pharmacology. According to the researchers, ITPP administration resulted in a significant increase in exercise capacity, endurance, and oxygen uptake, indicating that ITPP has the potential to be used as an ergogenic aid for physical activity. (R)
BehemothLabz offers ITPP for use in laboratory research purposes only.
Peroxisome proliferator-activated receptor (PPAR) agonist GW0742. It has a reputation for having therapeutic potential in the treatment of metabolic disorders like obesity, type 2 diabetes, and dyslipidemia. An essential transcription factor in the control of lipid metabolism and glucose homeostasis is PPAR. (R) (R)
Investigators thoroughly checked how GW0742 affected PPAR activation and whether it might be used to treat obesity and other disorders associated with it. In 2004, the Journal of Medicinal Chemistry published it. The research found GW0742 to be a highly effective and selective PPAR agonist, increasing fatty acid oxidation and glucose uptake in muscle cells, leading to improved insulin sensitivity. The researchers claim that GW0742 has the potential to be made into a therapeutic agent for the management of metabolic disorders. (R)
BehemothLabz offers GW0742 intended for use in laboratory research purposes only.
As a Rev-ErbA agonist, the synthetic substance SR9011 activates receptors in the body that are involved in controlling the circadian rhythm, metabolism, and energy expenditure. In animal studies, it has been discovered to boost metabolic rate, enhance lipid and glucose metabolism, and improve exercise performance. (R) (R)
According to a study done on mice, SR9011 treatment improved exercise capacity and endurance. The compound increased oxygen consumption and decreased the respiratory exchange ratio, which further supports the idea that fat was used more frequently as an energy source during exercise. Additionally, SR9011 increased insulin sensitivity and glucose tolerance, suggesting a potential therapeutic advantage for metabolic diseases like diabetes. (R)
Again, BehemothLabz offers SR9011 intended for use in laboratory research purposes only.
While Inositol Trispyrophosphate (ITPP) has not been validated as a cancer treatment or preventative, its potential impacts have been investigated in animal models and cell studies. It’s crucial to note that many substances display anti-cancer effects in cell cultures, including harmful chemicals, but these results don’t always translate to clinical significance. Most of these substances fail to progress beyond initial studies due to safety or efficacy issues. [R]
Hypoxia, or reduced oxygen levels, may trigger angiogenesis, the process of forming new blood vessels, which is essential for normal development and growth. However, in the context of cancer, angiogenesis may facilitate tumor development and the metastasis of cancer cells to different parts of the body. [R]
Studies on ITPP benefits indicate that it may have anti-cancer effects by potentially addressing hypoxia and reducing angiogenesis. By potentially inhibiting these mechanisms, ITPP might decrease tumor growth and the likelihood of metastasis. Research involving animal models and cells has explored ITPP’s impact on various cancers, such as pancreatic, colon, liver, and glioma, a type of tumor affecting the brain and spinal cord. [R]
However, the evidence is not entirely consistent. While some studies suggest that ITPP may slow tumor growth and metastasis by preventing angiogenesis, others have reported no beneficial effects. For instance, certain rat studies on glioblastoma (a form of glioma) found that ITPP did not improve survival rates and might even diminish the efficacy of radiation therapy. [R]
Inositol Trispyrophosphate (ITPP) is gaining attention for its potential to enhance how effectively red blood cells release oxygen. This characteristic positions ITPP as a potential solution for addressing hypoxia, a condition where tissues in the body lack sufficient oxygen. [R]
ITPP’s notable benefit lies in its capacity to modify hemoglobin’s oxygen affinity in red blood cells. By decreasing the red blood cells’ oxygen-binding ability, ITPP facilitates better oxygen delivery to tissues. This improvement is crucial in situations where tissues are deprived of oxygen, which may enhance overall cellular health and performance. [R]
Angiogenesis, the process of new blood vessel formation, is typically triggered by hypoxia to improve oxygen supply to tissues. However, excessive angiogenesis may lead to pathological conditions such as tumors and chronic diseases. Research indicates that ITPP may help to reduce angiogenesis, offering a therapeutic benefit. This effect is achieved by modulating key molecules such as Vascular Endothelial Growth Factor (VEGF) and hypoxia-inducible factor 1alpha (HIF-1α), which are essential in the angiogenesis process. [R]
ITPP’s potential to influence hypoxia markers extends beyond angiogenesis. By decreasing levels of VEGF and HIF-1α, ITPP may mitigate some of the adverse effects associated with chronic hypoxia. Lowering these markers not only reduces new blood vessel formation but also addresses the broader physiological response to low oxygen levels, which may include inflammation and tissue damage. [R]
Research in animal models, particularly mice, supports the hypothesis that ITPP may significantly enhance oxygen delivery to tissues. Research has demonstrated that administering ITPP reduces the oxygen-binding affinity of red blood cells, thereby boosting the oxygen supply to different tissues. This improved oxygen delivery may potentially mitigate the effects of hypoxia in conditions like chronic obstructive pulmonary disease (COPD), ischemic diseases, and other disorders marked by insufficient oxygen availability. [R]
Research involving ITPP (Inositol Trispyrophosphate) has shown promising results regarding its potential to enhance exercise capacity. In a particular study with mice models, ITPP administration was found to significantly boost maximal exercise capacity in a dose-dependent manner, with the highest reported increase being 57%. [R]
Further investigations into mice models with severe heart failure revealed that ITPP also potentially improved their exercise capacity. This was measured using treadmill tests, indicating that ITPP might be beneficial even in compromised cardiovascular conditions. [R]
Additionally, studies suggest that ITPP may enhance exercise performance. These findings indicate that ITPP may be a versatile and potential means to improve physical endurance and overall exercise capacity. [R]
GW0742 has demonstrated potential in promoting muscle regeneration and enhancing endurance, according to studies conducted on mouse models. This compound appears to accelerate the recovery of skeletal muscles following injury and improve running performance in trained mice. Additionally, GW0742 has shown the ability to potentially increase endurance capacity by reducing inflammation in skeletal muscles, particularly in obese female mice models, and inducing oxidative muscle remodeling akin to the effects of endurance training. [R]
Furthermore, GW0742 may also stimulate angiogenesis, the formation of new blood vessels, and potentially increase heart muscle mass. These benefits are largely attributed to the activation of PPARβ/δ, a receptor that supports the development of new blood vessels and the production of muscle fibers. [R]
GW0742 shows significant potential for enhancing cognitive function and protecting against cognitive dysfunction in various animal models. Studies indicate its ability to reduce radiation-induced cognitive impairment and diminish brain toxicity from beta amyloid proteins, commonly associated with Alzheimer’s disease. Furthermore, GW0742 potentially promotes brain cell maturation and has demonstrated effectiveness in potentially improving cognitive deficits linked to Alzheimer’s disease by enhancing fatty acid oxidation and reducing inflammation markers. In models of Parkinson’s disease, GW0742 potentially exhibits neuroprotective properties and prevents cognitive decline. [R][R]
It also addresses spatial memory deficits in diabetic mice models and mitigates cognitive impairment related to insulin resistance and high sugar intake in rat models. Moreover, GW0742 shows neuroprotective effects in cases of cerebral ischemia-reperfusion injury and reduces cell death in specific conditions. These findings underscore GW0742 as a potential therapeutic option for neurodegenerative disorders and cognitive impairments associated with metabolic conditions, warranting further exploration in clinical research. [R]
SR9011 has shown potential in promoting fat loss through distinct mechanisms. Firstly, it potentially increases the number of mitochondria within cells, which boosts metabolic rate even during periods of rest. This heightened metabolic activity enables the body to burn more calories efficiently. [R]
Secondly, SR9011 potentially facilitates fat loss by deactivating genes responsible for glucose uptake. By inhibiting these genes, SR9011 prompts the body to prioritize fat as its primary energy source instead of glucose. This metabolic shift enhances the potential of fat burning processes. [R]
These dual actions suggest that SR9011 may be a valuable compound for potentially enhancing metabolic activity and promoting efficient fat loss, making it an area of interest for further research into potential therapeutic applications. [R]
SR9011 shows the potential to enhance the recovery process through two key mechanisms. Firstly, it potentially reduces inflammation, which is crucial for minimizing tissue damage and facilitating quicker healing. By dampening inflammatory responses, SR9011 may aid the body in repairing injuries and recovering from stress more efficiently. [R]
Secondly, SR9011 potentially enhances cell regeneration, promoting faster healing. This boost in cellular renewal allows for the rapid replacement of damaged cells with healthy ones, thereby shortening recovery times. [R]
These potential benefits suggest that SR9011 might accelerate recovery by reducing inflammation and supporting enhanced cell regeneration, making it a promising candidate for further investigation in therapeutic applications to improve recovery processes.
Atlantic Capsules combine three active ingredients—ITPP, GW0742, and SR9011—each contributing unique benefits to the body. ITPP potentially improves the oxygen release capacity of red blood cells, which enhances oxygen delivery to tissues and is particularly helpful in low-oxygen conditions. It may also reduce the formation of new blood vessels and other markers of low oxygen, potentially benefiting conditions like certain cancers.
GW0742 potentially supports muscle recovery and increases endurance by speeding up muscle repair and lowering inflammation. It also has potential cognitive benefits, protecting against dysfunction in Alzheimer’s and Parkinson’s disease models and preventing cognitive issues linked to diabetes and insulin resistance. SR9011 supports fat loss by potentially increasing mitochondrial numbers, raising the metabolic rate during rest, and promoting fat use over glucose for energy.
It also potentially aids recovery by reducing inflammation and boosting cell regeneration. Together, these ingredients provide comprehensive benefits, including potential improved oxygen delivery, enhanced muscle regeneration and endurance, boosted cognitive function, effective fat burning, and accelerated recovery, making Atlantic Capsules a potential research compound for overall physical performance and recovery.
The safety and side effects of Atlantic Capsules, which contain ITPP, GW0742, and SR9011, are crucial to consider. While ITPP has shown promise in improving oxygen delivery and reducing excessive angiogenesis, its long-term safety and potential side effects in humans are not fully understood, with possible concerns including altered blood flow and oxygen distribution. GW0742, recognized for its ability to potentially support muscle repair and improve cognitive function, might pose risks due to its activity as a PPARβ/δ agonist, potentially affecting cardiovascular health and metabolic functions. SR9011, which facilitates potential fat loss and recovery, might lead to side effects related to its influence on metabolism and circadian rhythms, including possible disruptions in sleep patterns, metabolic changes, and effects on liver function. Comprehensive clinical trials and long-term studies are needed to fully assess the safety profile of these compounds and their combined effects in Atlantic Capsules.
Inositol Trispyrophosphate (ITPP) is a compound that potentially improves the ability of red blood cells to release oxygen. By altering the oxygen-binding properties of hemoglobin, ITPP enables red blood cells to deliver oxygen more effectively to tissues. This enhanced oxygen delivery may be especially helpful in conditions where tissues are lacking oxygen, such as hypoxia. Furthermore, ITPP may decrease angiogenesis and other indicators of low oxygen, potentially providing therapeutic advantages in diseases marked by excessive blood vessel formation, such as certain cancers.
GW0742 has demonstrated notable potential for enhancing muscle health through multiple mechanisms. It supports muscle regeneration by speeding up the repair of skeletal muscles after injury and reducing inflammation. Additionally, this compound potentially boosts endurance by enhancing running performance and promoting oxidative muscle remodeling, similar to the benefits seen with endurance training. These combined benefits suggest that GW0742 might be valuable for participants seeking to potentially improve muscle recovery, increase endurance, and maintain overall muscle health.
SR9011 exhibits promising potential in facilitating fat loss through multiple pathways. It potentially enhances mitochondrial density in cells, thereby increasing metabolic rate throughout resting periods, promoting heightened calorie expenditure. Moreover, SR9011 potentially suppresses genes that regulate glucose absorption, compelling the body to prioritize fat utilization as its primary energy source over glucose. This metabolic shift potentially enhances fat-burning efficiency, highlighting SR9011’s potential as a beneficial aid for managing weight and promoting metabolic well-being.
BehemothLabz is the best place to purchase Atlantis Capsules.
We have been around since 2014, supplying the highest-quality research compounds money can buy. Our products come with a 100% satisfaction guarantee, free and fast shipping, and a money-back guarantee on Atlantis Capsules.
Atlantis Capsules by BehemothLabz combine cutting-edge research compounds ITPP, GW0742, and SR9011, each carefully selected for their potential unique physiological benefits. ITPP possibly enhances oxygen delivery to tissues and potentially reduces angiogenesis, benefiting conditions like hypoxia and certain cancers. GW0742 potentially aids in muscle recovery, enhances endurance, and exhibits potential in safeguarding against cognitive decline in neurodegenerative conditions. SR9011 potentially promotes fat loss by increasing metabolic rate and encouraging fat utilization, alongside facilitating faster recovery through reduced inflammation and improved cell regeneration. These capsules provide a holistic strategy to improve physical performance, cognitive abilities, and metabolic well-being. BehemothLabz guarantees customer satisfaction with reliable shipping, a money-back policy, and attentive customer service, making them an excellent choice for premium research compounds.
BEHEMOTHLABZ DISCLAIMER
Please make sure you go through the Terms and Conditions, and please familiarize yourself with it as it is important. Please research the scientific uses of this product before making any purchases. Make note that the packaging and labels of the product may differ from those shown on the website.
Buying the product means you agree with our Terms and Conditions. You can contact our awesome customer service team at [email protected] if you are not fully satisfied with the product.
Customer satisfaction is our number-one priority!
All BehemothLabz products are strictly for LABORATORY AND RESEARCH PURPOSES ONLY. They are not to be used for any human or veterinary purposes.
Earl Guthrie –
Stacks arrived safely. Thanks.
Allan Akins –
I just received my order now. Thank you for the fast shipping. Can’t wait to try it right away. Will follow up soon with the results.